Clinical

The Princess of Wales is likely referencing adjuvant chemotherapy, but there is a growing field of immunoprevention, which seeks to target precancerous lesions or block heritable cancers.

Investigators examined the downstream effect of single-gene testing for guideline-recommended biomarkers on comprehensive genomic profiling in non–small cell lung cancer (NSCLC).

However, researchers saw higher risks of respiratory failure, longer stays in the intensive care unit, increased hospitalizations, and elevated mortality rates in patients with heart failure with reduced ejection fraction (HFrEF) taking the antihypotensive medication.

Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say.

Interferons have been a major treatment for myeloproliferative neoplasms (MPNs) for decades, but emerging therapies are expanding the treatment armamentarium, explained Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center.

The White House has called out the Republican Study Committee’s budget proposal for backing legislation that would put restrictions on abortion access; nearly 108,000 Americans died of drug overdoses in 2022; surgeons in Boston have transplanted a kidney from a genetically engineered pig into an ailing 62-year-old man.

CMS is highly likely to negotiate the price of the obesity medication semaglutide in the coming years; many health care providers are trying to determine whether their cyberattack insurance will help cover their losses after the Change Healthcare hack; the US life expectancy increased for the first time in 2 years.

Increased perceived economic burden (PEB) was associated with an increased risk of mortality and poorer health status among patients with acute decompensated heart failure (HF).

These findings, together with real-world data, could help inform risk classification of myasthenic crisis beyond known risk factors, such as infection.

Reducing or quitting smoking significantly lowered the risk of lung cancer in patients with chronic obstructive pulmonary disease (COPD) who smoked less than 30 pack-years in a recent study.

Patients with colorectal cancer (CRC) and spousal caregivers were found to benefit from a couple-based posttraumatic growth intervention visits in a randomized controlled study.

There is no cure for chronic lymphocytic leukemia (CLL), but new therapeutic options could extend survival, even in cases where the latest treatments have faltered.

A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.

Once-daily aprocitentan (Tryvio) is the first and only FDA-approved endothelin receptor antagonist for treating high blood pressure that remains uncontrolled despite other antihypertensive treatments.

These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).

Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, reports promising response rates and a good safety profile with JNJ-2113 in patients with moderate to severe plaque psoriasis.

The Duchenne muscular dystrophy (DMD) treatment vamorolone received FDA approval in October 2023 and is a less toxic alternative to conventional corticosteroids.

An expert reviews risk factors for type 1 diabetes including autoimmune disease and family history, along with the role of autoimmune antibody screening to enable early disease detection, though access to these specialized tests can be limited.

Posters reported the prevalence of autoimmune comorbidities among patients with vitiligo, demonstrating the need for earlier screenings and updated clinical guidelines.

Analysis of single-agent, combination, and novel bispecific antibodies revealed a positive landscape of treatment for patients with diffuse large B-cell lymphoma (DLBCL).

Ronald D. Alvarez, MD, MBA, provides closing commentary on the current ovarian cancer treatment landscape and the promising outlook over the next 20 years.

A medical professional examines the pivotal roles of molecular profiling, next-generation sequencing, and germline testing in guiding treatment decisions for ovarian cancer.

Jonathan Abbas, MD, compares the safety and effectiveness of different targeted agents and considerations when selecting a frontline regimen for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Posters presented showed that patients with vitiligo have a heightened risk of stigma and subsequent mental health issues.